

Congenital Hyperinsulinism Market Report 2032: Epidemiology, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

As per DelveInsight analysis, the Congenital Hyperinsulinism market is anticipated to witness growth at a considerable CAGR.

LAS VEGAS, NEVADA, UNITED STATES, March 21, 2024 /EINPresswire.com/ --

DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Congenital Hyperinsulinism, historical and

forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Congenital Hyperinsulinism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Congenital Hyperinsulinism Market Forecast](#)

Some of the key facts of the Congenital Hyperinsulinism Market Report:

The Congenital Hyperinsulinism market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

Key Congenital Hyperinsulinism Companies: Zealand Pharma, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger BioPharma-ceuticals, Crinetics, AmideBio, Xeris Pharmaceuticals, Hanmi Pharmaceutical, and others

Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

DelveInsight has analyzed mutation-specific data of Congenital Hyperinsulinism, which suggests that mutations in the ABCC8 and KCNJ11 genes are the most common causes of Congenital Hyperinsulinism while mutations in several other genes (GLUD1, GCK, HADH, SLC16A1, HNF4A, and HNF1A) are also involved in the development of Congenital Hyperinsulinism . In the United States, in 2021, mutations in ABCC8 and KCNJ11 genes accounted for 4,917 cases, while other

gene mutations accounted for 4,023 cases.

In the EU5 countries, the diagnosed prevalence of Congenital Hyperinsulinism was maximum in the United Kingdom with 2,398 cases, followed by Germany with 2,066 cases in 2021. While, the least number of cases were in Spain, with 1,286 cases in 2021 respectively.

In Japan, the diagnosed prevalence of Congenital Hyperinsulinism was 2,685 in 2021 growing at a CAGR of 1.0%.

The Congenital Hyperinsulinism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Hyperinsulinism pipeline products will significantly revolutionize the Congenital Hyperinsulinism market dynamics.

Congenital Hyperinsulinism Overview

Congenital Hyperinsulinism is a rare genetic disorder characterized by an overproduction of insulin, resulting in abnormally low blood sugar levels in infants and children. This condition arises from mutations in genes responsible for regulating insulin secretion within the pancreas. Symptoms may manifest as seizures, lethargy, poor feeding, and developmental delays. Timely diagnosis is crucial to mitigate potential long-term complications such as brain damage.

Treatment options encompass medication to stabilize blood sugar levels, frequent feedings, and in severe cases, surgical intervention involving the partial removal of the pancreas. Long-term monitoring is imperative to ensure proper growth and development. Providing supportive care and educational resources is essential for families affected by this condition.

Congenital Hyperinsulinism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congenital Hyperinsulinism Epidemiology Segmentation:

The Congenital Hyperinsulinism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Congenital Hyperinsulinism

Prevalent Cases of Congenital Hyperinsulinism by severity

Gender-specific Prevalence of Congenital Hyperinsulinism

Diagnosed Cases of Episodic and Chronic Congenital Hyperinsulinism

Download the report to understand which factors are driving Congenital Hyperinsulinism epidemiology trends @ [Congenital Hyperinsulinism Epidemiology Forecast](#)

Congenital Hyperinsulinism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Hyperinsulinism market or expected to get launched during the study period. The analysis covers Congenital Hyperinsulinism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Hyperinsulinism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Hyperinsulinism Therapies

Dasiglucagon

RZ358

Avexitide

CRN04777

ABG-023

HM1513

Congenital Hyperinsulinism Key Companies

Zealand Pharma

Eli Lilly

Novo Nordisk

Novartis

Rezolute

Eiger BioPharma-ceuticals

Crinetics

AmideBio

Xeris Pharmaceuticals

Hanmi Pharmaceutical

Congenital Hyperinsulinism Market Outlook

There is only one approved therapy for CHI in the market, namely, PROGLYCEM (diazoxide) – a

non-diuretic benzothiadiazole derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals. A number of children with CHI are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide/lanreotide are required in such children. Somatostatin receptor analogs (SSRIs), typically octreotide/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long-acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long-acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that severity of CHI may naturally reduce over time, the use of fixed-dose long-acting SSRAs may be considered disproportionate.

Scope of the Congenital Hyperinsulinism Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Congenital Hyperinsulinism Companies: Zealand Pharma, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Xeris Pharmaceuticals, Hanmi Pharmaceutical, and others

Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies

Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Congenital Hyperinsulinism Unmet Needs, KOL's views, Analyst's views, Congenital Hyperinsulinism Market Access and Reimbursement

To know more about Congenital Hyperinsulinism companies working in the treatment market, visit @ [Congenital Hyperinsulinism Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Congenital Hyperinsulinism Market Report Introduction
2. Executive Summary for Congenital Hyperinsulinism
3. SWOT analysis of Congenital Hyperinsulinism
4. Congenital Hyperinsulinism Patient Share (%) Overview at a Glance
5. Congenital Hyperinsulinism Market Overview at a Glance

6. Congenital Hyperinsulinism Disease Background and Overview
 7. Congenital Hyperinsulinism Epidemiology and Patient Population
 8. Country-Specific Patient Population of Congenital Hyperinsulinism
 9. Congenital Hyperinsulinism Current Treatment and Medical Practices
 10. Congenital Hyperinsulinism Unmet Needs
 11. Congenital Hyperinsulinism Emerging Therapies
 12. Congenital Hyperinsulinism Market Outlook
 13. Country-Wise Congenital Hyperinsulinism Market Analysis (2019–2032)
 14. Congenital Hyperinsulinism Market Access and Reimbursement of Therapies
 15. Congenital Hyperinsulinism Market Drivers
 16. Congenital Hyperinsulinism Market Barriers
 17. Congenital Hyperinsulinism Appendix
 18. Congenital Hyperinsulinism Report Methodology
 19. DelveInsight Capabilities
 20. Disclaimer
 21. About DelveInsight
- Related Reports:

Congenital Hyperinsulinism Pipeline

"Congenital Hyperinsulinism Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Congenital Hyperinsulinism market. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided, which includes the disease overview and Congenital Hyperinsulinism treatment guidelines.

Congenital Hyperinsulinism Epidemiology

DelveInsight's 'Congenital Hyperinsulinism Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Congenital Hyperinsulinism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market |

Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight :

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact:

Company Name: DelveInsight Business Research LLP

Contact Person: Kritika Rehani

Email: info@delveinsight.com

Contact No.: +14699457679

City: 304 S. Jones Blvd #2432, Las Vegas

State: Nevada (89107)

Country: United States

Website: <https://www.delveinsight.com/consulting>

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/697651977>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.